Amiodarone prophylaxis for atrial fibrillation in patients undergoing surgery for lung cancer: A controlled, randomized, double blinded trial. - PASCART

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-005246-20-DK

Enrollment

275

Registered

2008-02-15

Start date

2008-03-11

Completion date

Unknown

Last updated

2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation after lung resection due to cancer in the lung MedDRA version: 9.1 Level: LLT Classification code 10003658 Term: Atrial fibrillation MedDRA version: 9.1 Level: LLT Classification code 10025065 Term: Lung carcinoma cell type unspecified recurrent

Interventions

Trade Name: Cordarone Pharmaceutical Form: Tablet INN or Proposed INN: Amiodarone CAS Number: 19774824 Other descriptive name: Cordarone Concentration unit: mg milligram(s) Concentration type: equal C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Enlisted for lungresection due to pulmonary neoplasma 2) Elective surgery 3) Willingness of randomisation 4) Above 18 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1) Former pulmonary surgery performed 2) Former heart surgery 3) Resting heart beat below 40 beats/ min 4) AV-blockage of any degree 5) Paroxysmal, persistent or permanent atrial fibrillation or flutter 6) Former insidence of paroxysmal, persistent or permanent atrial fibrillation or flutter 7) Pregnant 8) Breastfeeding 9) Allergy towards the substances in cordarone

Design outcomes

Primary

Measure	Time frame
Main Objective: To reduce the incidence of atrial fibrillation after lung resection due to lung cancer;Secondary Objective: To compile the cost-effectiveness of the instituted prophylaxis;Primary end point(s): 1) Atrial fibrillation 2) Symptomatic atrial fibrillation 3) Length of stay	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026